DF
MCID: DNG003
MIFTS: 65

Dengue Disease (DF)

Categories: Genetic diseases, Infectious diseases, Liver diseases, Rare diseases

Aliases & Classifications for Dengue Disease

MalaCards integrated aliases for Dengue Disease:

Name: Dengue Disease 12 15 17
Dengue Fever 12 73 20 3 15 70
Dengue 54 42 44
Dengue Shock Syndrome 20 70
Df 20 3
Philippine Hemorrhagic Fever 20
Singapore Hemorrhagic Fever 20
Dengue Hemorrhagic Fever 20
Dengue Virus Infection 20
Thai Hemorrhagic Fever 20
Hemorrhagic Dengue 20
Classical Dengue 12
Breakbone Fever 12
Classic Dengue 12
Severe Dengue 70

Classifications:



Summaries for Dengue Disease

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 99828 Definition Dengue fever (DF), caused by dengue virus, is an arboviral disease characterized by an initial non-specific febrile illness that can sometimes progress to more severe forms manifesting capillary leakage and hemorrhage (dengue hemorrhagic fever, or DHF) and shock (dengue shock syndrome, or DSS). Epidemiology DF is found in the tropics worldwide, especially in Southeast Asia, the Pacific region, and the Americas, with 40% of the global population at risk. An estimated 50 to 100 million cases of DF, 500,000 hospitalizations, and 20,000 deaths occur yearly worldwide. Clinical description The vast majority of dengue virus infections result in DF, which is characterized by sudden onset of fever, malaise, headache (classically retro-orbital), and myalgia/arthralgia, often followed soon after by a petechial rash, which may be pruritic. In most cases, symptoms will resolve within 7 days without further complications. However, in a small minority of patients, a brief period of deffervescence is followed by worsening abdominal symptoms (pain, nausea, vomiting, diarrhea), thrombocytopenia, hemorrhage (DHF: epistaxis, bleeding gums, gastrointestinal bleeding) and a capillary leak syndrome (DSS: hemoconcentration, hypoalbuminemia, pleural effusion, shock). DHF/DSS are seen most often in children under the age of 15 years. Risk is greater with secondary heterologous infection by one of the four dengue virus serotypes, but severe disease may be seen with first infections. Etiology Over 25 different viruses cause viral hemorrhagic fever. Dengue virus belongs to the Flaviviridae family, genus Flavivirus. Four distinct serotypes, with significant strain variation, are recognized. Dengue viruses are maintained in humans and transmitted between them by the bite of infected mosquitoes, most commonly Aedes aegypti but also Aedes albopictus ). Person-to-person transmission has not been reported. Diagnostic methods Common diagnostic modalities include serologic testing by enzyme linked immunosorbent assay (ELISA) and reverse transcription polymerase chain reaction (RT-PCR). Virus isolation may also be performed in specialized laboratories. The viremic phase of DF/DHF is usually brief (first 3-5 days of illness), after which time detection of anti-dengue IgM antibodies, which appear as early as 2-4 days after disease onset, is the mainstay. Numerous commercial ELISA assays are available with varying degrees of sensitivity and specificity. Differential diagnosis DF is difficult to distinguish from a host of other febrile illnesses such as malaria and typhoid fever (see these terms), especially early in the course of disease before the rash appears. For DHF/DSS, other viral hemorrhagic fevers, leptospirosis, rickettsial infection (see these terms) and meningococcemia need to be excluded. Management and treatment As there is presently no antiviral drug available for DF/DHF, treatment is supportive, following the guidelines for treatment of severe septicemia. Insecticide-treated bed nets, room screens and elimination of larval development sites should be used in open-air settings to prevent further transmission. Prognosis Case-fatality rates for DF are less than 1% but may rise to as high as 40% in DHF/DSS, largely dependent upon whether access to advanced medical care exists. Children and persons with underlying chronic diseases such as diabetes, heart disease, and asthma are at increased risk. The most severe phase of disease usually lasts only a few days and survivors generally have no lasting sequelae.

MalaCards based summary : Dengue Disease, also known as dengue fever, is related to dengue hemorrhagic fever and dengue shock syndrome, and has symptoms including fever and pruritus. An important gene associated with Dengue Disease is NEAT1 (Nuclear Paraspeckle Assembly Transcript 1), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include endothelial, t cells and skin, and related phenotypes are fever and headache

Disease Ontology : 12 A viral infectious disease that results in infection, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted by Aedes mosquito bite. The infection has symptom fever, has symptom severe headache, has symptom severe pain behind the eyes, has symptom joint pain, has symptom muscle and bone pain, has symptom rash, and has symptom mild bleeding.

MedlinePlus : 42 Dengue is an infection caused by a virus. You can get it if an infected mosquito bites you. Dengue does not spread from person to person. It is common in warm, wet areas of the world. Outbreaks occur in the rainy season. Dengue is rare in the United States. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from your nose, gums, or under your skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. These forms of dengue are life-threatening. There is no specific treatment. Most people with dengue recover within 2 weeks. Until then, drinking lots of fluids, resting and taking non-aspirin fever-reducing medicines might help. People with the more severe forms of dengue usually need to go to the hospital and get fluids. To lower your risk when traveling to areas where dengue is found Wear insect repellent with DEET Wear clothes that cover your arms, legs and feet Close unscreened doors and windows

CDC : 3 Dengue viruses are spread to people through the bite of an infected Aedes species (Ae. aegypti or Ae. albopictus) mosquito. Dengue is common in more than 100 countries around the world. Forty percent of the world's population, about 3 billion people, live in areas with a risk of dengue. Dengue is often a leading cause of illness in areas with risk.

Wikipedia : 73 Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin... more...

Related Diseases for Dengue Disease

Diseases in the Dengue Virus family:

Dengue Disease

Diseases related to Dengue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 746)
# Related Disease Score Top Affiliating Genes
1 dengue hemorrhagic fever 32.1 IL10 IFNG IFNB1 ICAM1 CD209
2 dengue shock syndrome 32.0 SULT1A3 SENP8 IVNS1ABP CD209
3 leptospirosis 31.2 PIK3C2A IL10 IFNG
4 diarrhea 30.9 IL10 IFNG IFNB1 CD40LG
5 invasive aspergillosis 30.9 MBL2 IL10 IFNG
6 vasculitis 30.8 VCAM1 SULT1A3 MBL2 ICAM1 CD40LG
7 filariasis 30.8 IL10 IFNG CCL5
8 uveitis 30.7 IL10 IFNG ICAM1 CCL4
9 hemophagocytic lymphohistiocytosis 30.7 IL10 IFNG CCL5 CCL4
10 rubella 30.7 IL10 IFNG IFNB1 CD40LG
11 aspergillosis 30.7 MBL2 IL10 IFNG CD209 CCL5
12 hepatitis e 30.6 IFNG IFNB1 CD40LG
13 spotted fever 30.6 IL10 IFNG CCL5
14 neuritis 30.6 VCAM1 IL10 IFNG CCL5 CCL4
15 poliomyelitis 30.6 IL10 IFNG ICAM1
16 viral encephalitis 30.6 VCAM1 IL10 IFNB1 CCL5
17 polyradiculoneuropathy 30.6 IL10 IFNG CCL5 CCL4
18 conjunctivitis 30.6 IL10 IFNG ICAM1
19 glomerulonephritis 30.6 VCAM1 MBL2 ICAM1 CD40LG
20 lupus erythematosus 30.6 IL10 IFNG FCGR1A CD40LG
21 meningoencephalitis 30.5 IL10 CD40LG CCL5
22 proteasome-associated autoinflammatory syndrome 1 30.5 VCAM1 IL10 IFNG ICAM1 CCL5
23 stomatitis 30.5 IL10 IFNG IFNB1
24 q fever 30.5 MBL2 IL10 IFNG CCL5
25 cutaneous lupus erythematosus 30.5 IL10 IFNG ICAM1
26 respiratory failure 30.5 PIK3C2A IL10 ICAM1 CCL5
27 hepatitis c 30.5 IL10 IFNG IFNB1 IFI27
28 herpes simplex 30.5 IFNB1 HCFC1 CD209 CCL5
29 purpura 30.5 THPO IL10 IFNG
30 tick-borne encephalitis 30.5 IVNS1ABP IL10 IFNB1 CD209
31 lymphadenitis 30.4 IL10 IFNG ICAM1 CD209
32 neutropenia 30.4 THPO MBL2 IL11 IL10
33 newcastle disease 30.4 IVNS1ABP IFNB1 IFI27
34 exanthem 30.4 PIK3C2A IL10 IFNG
35 pulmonary edema 30.4 PIK3C2A IL10 ICAM1
36 toxic shock syndrome 30.4 IL10 IFNG CD40LG
37 sickle cell anemia 30.3 VCAM1 IL10 ICAM1 CD40LG
38 chickenpox 30.3 IL10 IFNG IFNB1
39 japanese encephalitis 30.3 IVNS1ABP IFNB1 CD209 CCL5
40 myocarditis 30.3 VCAM1 PIK3C2A IL10 IFNG ICAM1 CD40LG
41 aplastic anemia 30.3 VCAM1 THPO IL11 IL10 IFNG
42 acute disseminated encephalomyelitis 30.3 IL10 IFNB1 CCL4
43 otitis media 30.3 MBL2 IL10 IFNG ICAM1
44 mumps 30.3 IL10 IFNG IFNB1
45 visceral leishmaniasis 30.3 MBL2 IL10 IFNG ICAM1
46 acquired immunodeficiency syndrome 30.3 VCAM1 NEAT1 IL10 IFNG ICAM1 CD40LG
47 alcoholic hepatitis 30.3 IL10 IFNG ICAM1
48 trypanosomiasis 30.3 VCAM1 IL10 IFNG ICAM1
49 schistosomiasis 30.2 IL10 IFNG CD40LG
50 toxoplasmosis 30.2 IL10 IFNG CD40LG

Graphical network of the top 20 diseases related to Dengue Disease:



Diseases related to Dengue Disease

Symptoms & Phenotypes for Dengue Disease

Human phenotypes related to Dengue Disease:

31 (show all 22)
# Description HPO Frequency HPO Source Accession
1 fever 31 hallmark (90%) HP:0001945
2 headache 31 hallmark (90%) HP:0002315
3 abdominal pain 31 frequent (33%) HP:0002027
4 arthralgia 31 frequent (33%) HP:0002829
5 skin rash 31 frequent (33%) HP:0000988
6 pruritus 31 frequent (33%) HP:0000989
7 nausea and vomiting 31 occasional (7.5%) HP:0002017
8 hypotension 31 occasional (7.5%) HP:0002615
9 hepatomegaly 31 occasional (7.5%) HP:0002240
10 ascites 31 occasional (7.5%) HP:0001541
11 thrombocytopenia 31 occasional (7.5%) HP:0001873
12 gastrointestinal hemorrhage 31 occasional (7.5%) HP:0002239
13 epistaxis 31 occasional (7.5%) HP:0000421
14 gingival bleeding 31 occasional (7.5%) HP:0000225
15 petechiae 31 occasional (7.5%) HP:0000967
16 bruising susceptibility 31 occasional (7.5%) HP:0000978
17 lethargy 31 occasional (7.5%) HP:0001254
18 cerebral hemorrhage 31 occasional (7.5%) HP:0001342
19 diarrhea 31 occasional (7.5%) HP:0002014
20 leukopenia 31 occasional (7.5%) HP:0001882
21 hypoproteinemia 31 occasional (7.5%) HP:0003075
22 cardiorespiratory arrest 31 occasional (7.5%) HP:0006543

UMLS symptoms related to Dengue Disease:


fever; pruritus

MGI Mouse Phenotypes related to Dengue Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 CCL5 CD209 CD40LG FCGR1A ICAM1 IFNB1
2 immune system MP:0005387 9.36 CCL5 CD40LG FCGR1A ICAM1 IFNB1 IFNG

Drugs & Therapeutics for Dengue Disease

Drugs for Dengue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
2
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
3 Neurotransmitter Agents Phase 4
4 Histamine Antagonists Phase 4
5
Histamine Phosphate Phase 4 51-74-1 65513
6 Dermatologic Agents Phase 4
7 Histamine H1 Antagonists Phase 4
8 Anti-Allergic Agents Phase 4
9
Ivermectin Approved, Investigational, Vet_approved Phase 2, Phase 3 70288-86-7 6474909
10
tannic acid Approved Phase 3 1401-55-4
11
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
12
Montelukast Approved Phase 2, Phase 3 158966-92-8 5281040
13 Antiparasitic Agents Phase 2, Phase 3
14 Anti-Infective Agents Phase 2, Phase 3
15 Protective Agents Phase 3
16 Insect Repellents Phase 3
17 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
18 Respiratory System Agents Phase 2, Phase 3
19 Anti-Asthmatic Agents Phase 2, Phase 3
20 Hormone Antagonists Phase 2, Phase 3
21 Hormones Phase 2, Phase 3
22 Leukotriene Antagonists Phase 2, Phase 3
23 Vaccines Phase 3
24
chloroquine Approved, Investigational, Vet_approved Phase 1, Phase 2 54-05-7 2719
25
Ribavirin Approved Phase 2 36791-04-5 37542
26
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
27
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
28
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
29
Phenol Approved, Experimental Phase 2 108-95-2 996
30
Streptomycin Approved, Vet_approved Phase 2 57-92-1 19649
31
Metformin Approved Phase 1, Phase 2 657-24-9 4091 14219
32 Immunologic Factors Phase 2
33 Amebicides Phase 1, Phase 2
34 Antirheumatic Agents Phase 1, Phase 2
35 Antimalarials Phase 1, Phase 2
36 Chloroquine diphosphate Phase 1, Phase 2 50-63-5
37 Antiprotozoal Agents Phase 1, Phase 2
38 Antimetabolites Phase 2
39 Hydrocortisone hemisuccinate Phase 2
40 Hydrocortisone 17-butyrate 21-propionate Phase 2
41 Hemostatics Phase 2
42 Antiviral Agents Phase 2
43 Plasma-lyte 148 Phase 2
44 Hypoglycemic Agents Phase 1, Phase 2
45 Papaya Approved Phase 1
46
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
47
Aluminum sulfate Approved Phase 1 10043-01-3
48
Varespladib methyl Investigational Phase 1 172733-08-3
49 Gastrointestinal Agents Phase 1
50 Adjuvants, Immunologic Phase 1

Interventional clinical trials:

(show top 50) (show all 200)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN) Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 The Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as a Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
3 A Phase II/III, Randomized, Placebo Controlled Trial of Efficacy and Safety of Ivermectin in Children and Adult Patients With Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
4 Clinical Evaluation of Insect Repellent and Insecticide Treated Nets Against Malaria, JE & Dengue in Rural Communities in Lao PDR Unknown status NCT00938379 Phase 3 20% deet insect repellent;placebo control
5 Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
6 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico Completed NCT02979535 Phase 3
7 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
8 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia Completed NCT02993757 Phase 3
9 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT01374516 Phase 3
10 An Open-Label, Phase 3 Trial to Investigate the Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) at the End of Shelf Life in Healthy Adults in Non-Endemic Country(Ies) for Dengue Completed NCT03771963 Phase 3
11 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Demonstrate Lot-to-Lot Consistency of 3 Lots of a Tetravalent Dengue Vaccine Candidate in Healthy Adults in Non-Endemic Country(Ies) for Dengue Completed NCT03423173 Phase 3
12 Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru Completed NCT01436396 Phase 3
13 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
14 Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico Completed NCT01411241 Phase 3
15 A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepatitis A Virus (Inactivated) Vaccine in Healthy Subjects Aged 18 to 60 Years in Non-endemic Country(Ies) for Dengue Completed NCT03525119 Phase 3
16 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescent Subjects in Non-Endemic Area(s) for Dengue Completed NCT03341637 Phase 3
17 A Randomized, Observer-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever YF-17D Vaccine Administered Concomitantly and Sequentially in Healthy Subjects Aged 18 to 60 Years in Non-Endemic Country(Ies) Completed NCT03342898 Phase 3 Placebo
18 Albumin 5% as Resuscitation in Adult Dengue Fever Patients With Plasma Leakage Recruiting NCT04076254 Phase 3 Albumins;Fluid
19 Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients: a Multicenter Randomized, Double-blind, Placebo Controlled, Superiority Trial Recruiting NCT04673422 Phase 2, Phase 3 Montelukast;Placebo
20 A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Areas Non-Endemic for Dengue Active, not recruiting NCT03999996 Phase 3
21 Phase III Trial to Evaluate Efficacy and Safety of a Dengue 1,2,3,4 (Attenuated) Vaccine Active, not recruiting NCT02406729 Phase 3
22 Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old Active, not recruiting NCT02747927 Phase 3 Placebo
23 A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscular Recombinant 9-Valent Human Papillomavirus (9vHPV) Vaccine in Subjects Aged ≥9 to <15 Years in an Endemic Country for Dengue Not yet recruiting NCT04313244 Phase 3
24 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines Terminated NCT02992418 Phase 3
25 The Effect of Chloroquine in the Treatment of Patients With Dengue Unknown status NCT00849602 Phase 1, Phase 2 Placebo;Chloroquine
26 Phase II, Step-wise, Randomized, Double-blind, Controlled Clinical Trial for Safety and Immunogenicity Evaluation of a Lyophilized Formulation of Dengue 1,2,3,4 (Attenuated) Vaccine in Healthy Adults Unknown status NCT01696422 Phase 2
27 Syndrome of Fever Associated With Bleeding of Chinese and Western Medicine Diagnosis and Treatment of Infectious Diseases Plans and Severe Clinical Treatment Research Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
28 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
29 Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Completed NCT03432442 Phase 2 Ivermectin
30 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
31 Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children Completed NCT00468858 Phase 2
32 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore Completed NCT02824198 Phase 2
33 Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
34 Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3- Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines Completed NCT02628444 Phase 2
35 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America Completed NCT02623725 Phase 2
36 Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore Completed NCT00880893 Phase 2
37 A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America Completed NCT02302066 Phase 2
38 An Open-Label, Phase 2 Trial to Investigate the Humoral and Cell-Mediated Immune Responses and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Flavivirus-Naïve and Dengue-Immune Healthy Adults Completed NCT03746015 Phase 2
39 Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine Completed NCT00730288 Phase 2
40 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults. Completed NCT01488890 Phase 2
41 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in South America Completed NCT01187433 Phase 2
42 Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years Completed NCT00740155 Phase 2
43 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT00993447 Phase 2
44 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru Completed NCT00788151 Phase 2
45 Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
46 Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India. Completed NCT01550289 Phase 2
47 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam Completed NCT00875524 Phase 2
48 Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand Completed NCT00842530 Phase 2
49 A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Comparison of Recombinant Factor VIIa (NovoSeven®) and Standard Haemostatic Replacement Therapy in Patients With Dengue Haemorrhagic Fever Completed NCT01601613 Phase 2 activated recombinant human factor VII;placebo
50 Celgosivir Proof of Concept Trial for Treatment of Acute Dengue Fever Completed NCT01619969 Phase 1, Phase 2 celgosivir;placebo

Search NIH Clinical Center for Dengue Disease

Cochrane evidence based reviews: dengue

Genetic Tests for Dengue Disease

Anatomical Context for Dengue Disease

MalaCards organs/tissues related to Dengue Disease:

40
Endothelial, T Cells, Skin, Monocytes, Kidney, Liver, Spleen

Publications for Dengue Disease

Articles related to Dengue Disease:

(show top 50) (show all 5565)
# Title Authors PMID Year
1
Micronutrient Supplementation and Clinical Outcomes in Patients with Dengue Fever. 61 42
33258437 2021
2
Scaling up of Eco-Bio-Social Strategy to Control Aedes aegypti in Highly Vulnerable Areas in Fortaleza, Brazil: A Cluster, Non-Randomized Controlled Trial Protocol. 42
33572650 2021
3
Tracking infectious diseases in a warming world. 42
33187953 2020
4
Cardiac tamponade in a patient with dengue fever and lupus nephritis: a case report. 54 61
20089524 2010
5
Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation. 61 54
19822367 2009
6
Early diagnosis of dengue virus infection by detection of dengue viral antigen in peripheral blood mononuclear cell. 61 54
19755928 2009
7
The relationship of interacting immunological components in dengue pathogenesis. 61 54
19941667 2009
8
Skin lesions in hospitalized cases of dengue Fever. 61 54
18940116 2008
9
Evaluation of two new commercial tests for the diagnosis of acute dengue virus infection using NS1 antigen detection in human serum. 61 54
18714359 2008
10
Analysis of antibody response in human dengue patients from the Mexican coast using recombinant antigens. 54 61
18279077 2008
11
Antiplatelet autoantibodies elicited by dengue virus non-structural protein 1 cause thrombocytopenia and mortality in mice. 54 61
17958746 2007
12
Characterization of dengue virus serotype 1 in epidemics in Porto Velho, Rondônia, in 2001-2003. 61 54
17653458 2007
13
The distribution of DEN infected people in Dushan and Xingyi area of Yunnan-Guizhou Plateau, China. 54 61
17257502 2006
14
Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). 61 54
17005690 2006
15
Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome. 54 61
17006283 2006
16
DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus. 61 54
16140430 2006
17
An outbreak of dengue fever in periurban slums of Chandigarh, India, with special reference to entomological and climatic factors. 61 54
16385170 2005
18
[A variant in the CD209 (DC-SIGN) promoter is associated with severity of dengue disease]. 61 54
16274635 2005
19
Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion. 54 61
16103156 2005
20
Optimized diagnosis of acute dengue fever in Swedish travelers by a combination of reverse transcription-PCR and immunoglobulin M detection. 54 61
15956408 2005
21
Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections. 54 61
15498040 2004
22
Field- and laboratory-based active dengue surveillance in Chennai, Tamil Nadu, India: observations before and during the 2001 dengue epidemic. 54 61
15525913 2004
23
IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. 54 61
15122797 2004
24
Dengue fever mimicking plasma cell leukemia. 54 61
12873179 2003
25
Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. 54 61
12436482 2003
26
High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. 54 61
12355369 2002
27
Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. 54 61
11724841 2001
28
Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2. 54 61
11504411 2001
29
Cytotoxic factor-autoantibodies: possible role in the pathogenesis of dengue haemorrhagic fever. 61 54
11335136 2001
30
Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction. 54 61
10928995 2000
31
Infection of five human liver cell lines by dengue-2 virus. 61 54
10686026 2000
32
An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. 54 61
10698995 2000
33
Comparison of PanBio dengue duo enzyme-linked immunosorbent assay (ELISA) and MRL dengue fever virus immunoglobulin M capture ELISA for diagnosis of dengue virus infections in Southeast Asia. 61 54
10473522 1999
34
Status of antioxidants and other biochemical abnormalities in children with dengue fever. 61 54
10191585 1999
35
Production of cytotoxic factor by peripheral blood mononuclear cells (PBMC) in patients with dengue haemorrhagic fever. 61 54
9649218 1998
36
Immunoglobulin A-specific capture enzyme-linked immunosorbent assay for diagnosis of dengue fever. 54 61
9574674 1998
37
Detection of flaviviruses by reverse transcriptase-polymerase chain reaction with the universal primer set. 54 61
9130232 1997
38
Dengue. Muscle biopsy findings in 15 patients. 61 54
8274073 1993
39
Study of anti-dengue NS1 antibody by western blot. 54 61
2149144 1990
40
Capsid integrity quantitative PCR to determine virus infectivity in environmental and food applications - A systematic review. 61
33490943 2021
41
Internet of medical things (IoMT)-integrated biosensors for point-of-care testing of infectious diseases. 61
33596516 2021
42
Epidemiological trends of imported infectious diseases in Japan: Analysis of imported 2-year infectious disease registry data. 61
33309629 2021
43
Role of cytokines produced by T helper immune-modulators in dengue pathogenesis: A systematic review and meta-analysis. 61
33421421 2021
44
Current Knowledge and Ecological and Human Impact Variables Involved in the Distribution of the Dengue Virus by Bats in the Americas. 61
33439764 2021
45
Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials. 61
33212068 2021
46
Twenty-Two years of dengue fever (1996-2017): an epidemiological study in a Brazilian city. 61
31468989 2021
47
Changes in the dynamics of dengue incidence in South and Central America are possibly due to cross-population immunity after Zika virus epidemics. 61
33190402 2021
48
Dengue and metabolomics in humans. 61
33712974 2021
49
Covid-19 and dengue: Double punches for dengue-endemic countries in Asia. 61
32946149 2021
50
A case of dengue fever that should be considered as imported infectious disease with digestive symptoms. 61
33768451 2021

Variations for Dengue Disease

Expression for Dengue Disease

LifeMap Discovery
Genes differentially expressed in tissues of Dengue Disease patients vs. healthy controls: 35 (show top 50) (show all 93)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon alpha inducible protein 27 Blood + 4.85 0.000
2 RRM2 ribonucleotide reductase regulatory subunit M2 Blood + 4.48 0.000
3 CEP55 centrosomal protein 55 Blood + 4.33 0.000
4 BIRC5 baculoviral IAP repeat containing 5 Blood + 4.30 0.000
5 XIST X inactive specific transcript Blood - 4.25 0.009
6 CD38 CD38 molecule Blood + 4.23 0.000
7 DLGAP5 DLG associated protein 5 Blood + 4.10 0.000
8 BUB1 BUB1 mitotic checkpoint serine/threonine kinase Blood + 4.08 0.000
9 IGHM immunoglobulin heavy constant mu Blood + 4.04 0.000
10 MCM10 minichromosome maintenance 10 replication initiation factor Blood + 3.99 0.000
11 SHCBP1 SHC binding and spindle associated 1 Blood + 3.97 0.000
12 PBK PDZ binding kinase Blood + 3.97 0.000
13 TYMS thymidylate synthetase Blood + 3.96 0.000
14 PI3 peptidase inhibitor 3 Blood - 3.93 0.000
15 CDCA2 cell division cycle associated 2 Blood + 3.91 0.000
16 SESN3 sestrin 3 Blood - 3.90 0.000
17 HMMR hyaluronan mediated motility receptor Blood + 3.83 0.000
18 MKI67 marker of proliferation Ki-67 Blood + 3.83 0.000
19 ZWINT ZW10 interacting kinetochore protein Blood + 3.83 0.000
20 DTL denticleless E3 ubiquitin protein ligase homolog Blood + 3.80 0.000
21 CDK1 cyclin dependent kinase 1 Blood + 3.78 0.000
22 NCAPG non-SMC condensin I complex subunit G Blood + 3.76 0.000
23 CDT1 chromatin licensing and DNA replication factor 1 Blood + 3.76 0.000
24 SPC25 SPC25 component of NDC80 kinetochore complex Blood + 3.75 0.000
25 CDC20 cell division cycle 20 Blood + 3.73 0.000
26 CNTNAP3 contactin associated protein family member 3 Blood - 3.72 0.000
27 TOP2A DNA topoisomerase II alpha Blood + 3.71 0.000
28 CCN3 cellular communication network factor 3 Blood - 3.71 0.000
29 EIF1AY eukaryotic translation initiation factor 1A Y-linked Blood + 3.69 0.015
30 CCNB2 cyclin B2 Blood + 3.62 0.000
31 CDKN3 cyclin dependent kinase inhibitor 3 Blood + 3.62 0.000
32 PCLAF PCNA clamp associated factor Blood + 3.61 0.000
33 KIF2C kinesin family member 2C Blood + 3.60 0.000
34 TK1 thymidine kinase 1 Blood + 3.59 0.000
35 RPS4Y1 ribosomal protein S4 Y-linked 1 Blood + 3.57 0.017
36 TTK TTK protein kinase Blood + 3.56 0.000
37 CDC6 cell division cycle 6 Blood + 3.56 0.000
38 CAV1 caveolin 1 Blood + 3.56 0.000
39 CENPA centromere protein A Blood + 3.54 0.000
40 CYAT1 immunoglobulin lambda light chain-like Blood + 3.52 0.000
41 ASPM assembly factor for spindle microtubules Blood + 3.52 0.000
42 OR2W3 olfactory receptor family 2 subfamily W member 3 Blood - 3.51 0.000
43 UHRF1 ubiquitin like with PHD and ring finger domains 1 Blood + 3.50 0.000
44 SELENBP1 selenium binding protein 1 Blood - 3.50 0.000
45 GINS2 GINS complex subunit 2 Blood + 3.49 0.000
46 MELK maternal embryonic leucine zipper kinase Blood + 3.47 0.000
47 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Blood + 3.47 0.000
48 CHEK1 checkpoint kinase 1 Blood + 3.46 0.000
49 CCNB1 cyclin B1 Blood + 3.45 0.000
50 KIF11 kinesin family member 11 Blood + 3.42 0.000
Search GEO for disease gene expression data for Dengue Disease.

Pathways for Dengue Disease

Pathways related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 VCAM1 MBL2 IL11 IL10 IFNG IFNB1
2
Show member pathways
13.47 THPO IL11 IL10 IFNG IFNB1 ICAM1
3
Show member pathways
12.9 VCAM1 MBL2 IL10 IFNG IFNB1 ICAM1
4
Show member pathways
12.81 VCAM1 IL11 IL10 IFNG IFNB1 IFI27
5
Show member pathways
12.75 IFNG IFNB1 ICAM1 CD209 CCL5
6 12.52 VCAM1 IL10 IFNG CD40LG CCL5
7
Show member pathways
12.4 VCAM1 IFNG IFNB1 IFI27 ICAM1 FCGR1A
8
Show member pathways
12.35 THPO IL11 IL10 IFNG IFNB1
9
Show member pathways
12.34 VCAM1 IL10 ICAM1 CCL4
10
Show member pathways
12.22 THPO IL10 IFNG IFNB1 IFI27
11
Show member pathways
12.21 IL10 IFNG FCGR1A CD40LG
12 12.15 IL10 IFNG IFNB1 FCGR1A CD209
13 12.04 VCAM1 ICAM1 FCGR1A CD40LG
14 11.93 VCAM1 IFNB1 ICAM1 CCL5
15 11.89 VCAM1 ICAM1 CD40LG CCL4
16 11.83 MBL2 IL10 ICAM1 FCGR1A
17 11.83 THPO IL11 IL10 IFNG CD209
18 11.82 THPO IL11 FCGR1A
19 11.81 IL11 IFNG ICAM1 CCL5
20 11.68 IL10 IFNG IFNB1 CD209
21 11.6 VCAM1 IL10 ICAM1 CD40LG
22
Show member pathways
11.56 VCAM1 IFNG ICAM1 CD40LG
23 11.44 VCAM1 IFNG ICAM1
24 11.4 IL10 ICAM1 CCL5 CCL4
25 11.34 IFNG IFNB1 ICAM1
26
Show member pathways
11.32 IL10 IFNG CCL4
27 11.19 VCAM1 IL10 IFNG ICAM1
28 10.96 THPO IL11 IL10 CD40LG CCL5 CCL4
29 10.92 IL11 IL10 IFNG IFNB1
30 10.72 VCAM1 IL10 IFNG ICAM1 CD40LG

GO Terms for Dengue Disease

Cellular components related to Dengue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 THPO MBL2 IL11 IL10 IFNG IFNB1
2 extracellular space GO:0005615 9.36 VCAM1 THPO MBL2 IL11 IL10 IFNG

Biological processes related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 10 IVNS1ABP IFI27 ICAM1 HCFC1 CD209
2 immune response GO:0006955 9.88 IL10 IFNG FCGR1A CD40LG CCL5 CCL4
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.86 THPO ICAM1 CCL5 CCL4
4 regulation of immune response GO:0050776 9.85 VCAM1 ICAM1 FCGR1A CD40LG
5 cellular response to tumor necrosis factor GO:0071356 9.78 VCAM1 ICAM1 CCL5 CCL4
6 cellular response to interferon-gamma GO:0071346 9.77 ICAM1 CCL5 CCL4
7 cellular response to interleukin-1 GO:0071347 9.75 ICAM1 CCL5 CCL4
8 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.69 VCAM1 ICAM1 CD209
9 interferon-gamma-mediated signaling pathway GO:0060333 9.67 VCAM1 IFNG ICAM1 FCGR1A
10 response to virus GO:0009615 9.65 IVNS1ABP IFNG IFNB1 CCL5 CCL4
11 negative regulation of endothelial cell apoptotic process GO:2000352 9.63 IL11 IL10 ICAM1
12 positive regulation of T cell proliferation GO:0042102 9.62 VCAM1 CD40LG CD209 CCL5
13 B cell proliferation GO:0042100 9.61 IL10 IFNB1 CD40LG
14 positive regulation of signaling receptor activity GO:2000273 9.59 IL10 IFNG
15 negative regulation by host of viral transcription GO:0043922 9.58 CCL5 CCL4
16 positive regulation of MHC class II biosynthetic process GO:0045348 9.57 IL10 IFNG
17 B cell differentiation GO:0030183 9.55 VCAM1 IL11 IL10 IFNB1 CD40LG
18 regulation of complement-dependent cytotoxicity GO:1903659 9.54 IL11 IL10
19 positive regulation of natural killer cell chemotaxis GO:2000503 9.52 CCL5 CCL4
20 cytokine-mediated signaling pathway GO:0019221 9.5 VCAM1 IL11 IL10 IFNB1 ICAM1 CCL5
21 membrane to membrane docking GO:0022614 9.49 VCAM1 ICAM1
22 leukocyte cell-cell adhesion GO:0007159 9.02 VCAM1 ICAM1 CD40LG CD209 CCL5

Molecular functions related to Dengue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 THPO IL11 IL10 IFNG IFNB1 CD40LG
2 CCR5 chemokine receptor binding GO:0031730 9.16 CCL5 CCL4
3 CCR1 chemokine receptor binding GO:0031726 8.96 CCL5 CCL4

Sources for Dengue Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....